Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Compared with Sorafenib As First-Line Treatment in Advanced Hepatocellular Carcinoma in Singapore
Expert Review of Pharmacoeconomics & Outcomes Research（2024）
Key words
Atezolizumab,bevacizumab,cost-effectiveness,hepatocellular carcinoma,programmed death ligand-1,sorafenib
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined